Research we fund
Our Research Strategy
Our ambitious Research Strategy: how we'll invest in the most innovative research to create a step change in our knowledge of prostate cancer.
Why do we fund what we fund?FAB4-guided P4 immune therapy for prostate cancer
Funded research by Dr Sophie Papa of King's College London into whether the protein drug FAB4 could guide certain immune white blood cells to migrate into and attack prostate cancer.
A new method to detect bone cancers that have spread from the prostate (metastases) and monitor their response to treatment
Funded research by Prof. Gary Cook of St Thomas' Hospital, London into the use of 99mTc maraciclatide SPECT imaging to detect and measure the treatment response of bone metastases.
Developing a new localised immunotherapy for advanced prostate cancer
Funded research by Dr. Christine Galustian of King's College London into enabling immune system therapy proteins to stay at the site of tumours rather than circulate.
Development of new blood based markers to measure drug effectiveness and to personalise treatment in prostate cancer patients.
Funded research by Dr Marco Gerlinger of Barts Cancer institute into whether targeting circulating tumour DNA can give a better picture of individual treatment response and suitability.
A pilot study of a nurse-led intervention in primary care providing tailored advice and support to prostate cancer survivors on emotional and physical issues
Funded research by Prof. Eila Watson of Oxford Brookes University into the impact on men's quality of life of a nurse-led intervention following treatment.
Helping men to manage hot flushes and night sweats following prostate cancer treatments
Funded research by Prof. Myra Hunter of King's College London into a self-management treatment to help with the side-effects of hormone treatment.
New drug targets for the treatment of advanced prostate cancer
Funded research by Prof. Iain McEwan of Aberdeen University into whether blocking the androgen receptor protein can improve the effectiveness of hormone therapy.
Improving radiotherapy treatment of prostate cancer
Funded research by Prof. Kevin Prise of Queen's University Belfast into improving existing radiotherapy treatments using drugs that prevent DNA repair.
Targeting a protein to treat prostate cancer that is no longer responding to hormone therapy
Funded research by Dr Matthew David Lloyd of Bath University into whether manipulating the AMACR protein can help prevent drug resistance.
Improved initial diagnosis and localisation of prostate cancer
Funded research by Prof Reyer Zwiggelaar of Aberystwyth University into combining MRI with ultrasound information to improve diagnosis and localisation.
Prohibitin: a new way to slow prostate cancer growth
Professor Bevan and her team have been studying prohibitin , a protein that controls prostate cancer growth, since 2004. In this project, they have found a way to manipulate prohibitin levels, and turn it into a potential treatment for prostate cancer.
Characterising prostate cancer cells in blood
Funded research by Alice Hartley of Newcastle University into circulating tumour cells and whether they predict the effectiveness of hormone treatment.
Characterisation of a potential therapeutic target to treat advanced prostate cancer
Funded research by Dr Kelly Coffey of Newcastle University into why hormone therapy resistance occurs, and what happens to certain proteins when prostate cancer cells stop responding to hormone therapy.
Nanomedicine for prostate cancer
Funded research by Dr Wafa Al-Jamal of Queen's University Belfast into ways of targeting chemotherapy drugs directly to cancerous cells.
Precision Medicine for a subtype of prostate cancer associated with loss of the gene CHD1
Funded research by Prof. Johann de Bono of the Institute of Cancer Research into whether cancers resistant to abiraterone, enzalutamide and cabazitaxel are related to the loss of a DNA repair gene.
Predicting and reducing side-effects in prostate cancer therapy
Funded research by Professor Charlotte Bevan of Imperial College London into the development of a precise way of observing androgens.
Search for a new way to identify and treat advanced prostate cancer
Funded research by Dr Tania Maffucci of Queen Mary University of London into the implications of a recently discovered protein found mainly in prostate cancer cells.
Developing imaging methods to better assess the spread of prostate cancer to other body sites
Funded research by Dr Shonit Punwani of University College London into whether whole body MRI can be used as a more sensitive means of detecting metastasis.
Identification of genetic changes that drive aggressive prostate cancer progression
Looking for genetic changes in men with prostate cancer that are able to drive the disease to a more aggressive stage.
Can suppression of a stem cell control gene stop prostate cancer spreading?
Funded research by Prof. Norman Maitland at the University of York into the loss of latexin and its relationship to aggressive cancer.
Understanding how to improve the lives of men living with prostate cancer
Funded research by Dr Anna Gavin of Queen's University Belfast into quality of life following treatment and how it can be improved.
Does the absence of a protein, known as DARC, increase prostate cancer severity in African-Caribbean men?
Funded research by Dr Christine Galustian of King's College London into whether the absence of the DARC protein in Black men is related to the development of prostate cancer.
A new approach to testing markers of prostate cancer
Funded research by Dr Chris Parker of the Institute of Cancer Research into better ways of distinguishing between aggressive and indolent forms of prostate cancer using samples from 714 men undergoing a template mapping biopsy.
What changes occur to make men with prostate cancer stop responding to therapy?
Funded research by Dr. Joanne Edwards of Glasgow University into IKKa and IKKb and the influence they have on hormone resistance.
How do the molecules Sprouty2 and PI3/AKT promote growth of prostate cancer?
Funded research by Prof. Hing Leung of Glasgow University into the relationship between the molecules SPRY2 and PI3K/AKT and the implications for metastasis and hormone resistance.